Celldex Therapeutics Inc（CLDX）の株式分析CLDXCelldex Therapeutics Inc

Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

Celldex Therapeutics Inc is currently trading at $39.12, which is below the average analyst price target of $53, indicating potential upside. However, the RSI is at 28.34, suggesting the stock is oversold and may not be a strong buy right now. Additionally, the company reported a significant net loss of $78.7 million in Q1 2026, which raises concerns about its financial health. The main risk is the ongoing investigation into fiduciary breaches, which could negatively impact investor sentiment.

7 analysts cover CLDX: 4 rate it Buy, 3 Hold and 0 Sell. The average price target is 55.00.